NCT07587515RecruitingPhase 1/2
Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration
Open-Label, Multiple Ascending Dose Phase 1b/2a Study of the Safety and Tolerability of Intravitreal (IVT) EYC-0305 in Patients With Neovascular Age-Related Macular Degeneration
Source: ClinicalTrials.gov · Last updated 9 Oct 2026
Brief summary (registry, in English)
This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 8 May 2026
- Start date
- 19 May 2026
- Primary completion date
- 31 May 2028
- Lead sponsor
- Eyconis INC.
- Diseases
- Macular degeneration
- NCT number
- NCT07587515
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 30
- From 19 May 2026 to the primary completion date, 31 May 2028
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent psychiatric or medical condition that in the opinion of the Investigator will interfere with study participation or completion
Other illness
- Known hypersensitivity or known allergy that would preclude study drug administration
- Inability to obtain ophthalmic imaging, eg, due to media opacity, inadequate pupillary dilation, allergy to fluorescein dye or lack of venous access
- Uncontrolled diabetes mellitus
- History of cerebrovascular accident (CVA) or myocardial infarction within 180 days of the Day 1 visit
- Renal failure, dialysis, or history of renal transplant
Other
- Pregnant or breastfeeding women
Who the study is looking for
- Men or women 50 years and older with neovascular (wet) AMD meeting all study-specified eligibility criteria
- Willing and able to comply with clinic visits and study-related procedures
- Provide signed informed consent
Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Bellaire, TX Coordinator of this site? Confirm its status | Bellaire | United States | Recruiting |
| Beverly Hills, CA Coordinator of this site? Confirm its status | Beverly Hills | United States | Recruiting |
| Erie, PA Coordinator of this site? Confirm its status | Erie | United States | Recruiting |
| McAllen, TX Coordinator of this site? Confirm its status | McAllen | United States | Recruiting |
| Modesto, CA Coordinator of this site? Confirm its status | Modesto | United States | Recruiting |
| The Woodlands, TX Coordinator of this site? Confirm its status | The Woodlands | United States | Recruiting |
| Wake Forest, NC Coordinator of this site? Confirm its status | Wake Forest | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.